Association between cytochrome P450 2D6 genotype and harm avoidance

被引:40
|
作者
Roberts, RL
Luty, SE
Mulder, RT
Joyce, PR
Kennedy, MA
机构
[1] Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand
[2] Christchurch Sch Med & Hlth Sci, Dept Psychol Med, Christchurch, New Zealand
关键词
CYP2D6; genotype; personality; brain; harm avoidance; novelty seeking;
D O I
10.1002/ajmg.b.20163
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Genetic polymorphisms within the serotonergic and dopaminergic neurotransmitter systems may be associated with heightened harm avoidance and novelty seeking. It is also conceivable that polymorphisms in enzymes that mediate the metabolism of endogenous amines within the brain may influence these components of temperament. The CYP2D6 enzyme is expressed at low levels in the brain, and has been shown to mediate the formation of the neurotransmitters serotonin and dopamine from trace amines. Some 5-10% of Caucasians are CYP2D6 deficient due to inactivating mutations in the CYP2D6 gene, and are termed poor metabolizers (PMs). In this study, we investigated whether temperament varied significantly between PMs and CYP2D6 extensive metabolizers (EMs) using the Temperament and Character Inventory (TCI). CYP2D6 genotypes were determined for 121 depressed patients. Of these patients, 113 were inferred from genotype as being EMs and eight as PMs. A significant difference in temperament was observed between inferred CYP2D6 EM and PM individuals. CYP2D6 PMs had significantly lower harm avoidance scores (P = 0.003) than EMs. Furthermore, analysis of the harm avoidance sub-scales revealed that the CYP2D6 PMs scored significantly lower on "fear of uncertainty" (P < 0.001), fatigability (P = 0.009), and shyness (P = 0.038) than EMs, but did not differ significantly from EMs on the worry/pessimism sub-scale. No significant difference in character scores was detected between inferred CYP2D6 EMs and PMs. Our findings suggest that the CYP2D6 polymorphism may impact on personality, and one potential mechanism for this would be by influencing the generation of endogenous neurotransmitters in the brain. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:90 / 93
页数:4
相关论文
共 50 条
  • [1] Association study between cytochrome P450 2D6 genotype and patients with methamphetamine dependence
    Otani, Kyohei
    Ujike, Hiroshi
    Sakai, Ayumu
    Tanaka, Yuji
    Uchida, Naohiko
    Nomura, Akira
    Morita, Yukitaka
    Kishimoto, Makiko
    Morio, Akiko
    Inada, Toshiya
    Harano, Mutsuo
    Komiyama, Tokutaro
    Hori, Toru
    Yamada, Mitsuhiko
    Sekine, Yoshimoto
    Iwata, Nakao
    Iyo, Masaomi
    Sora, Ichiro
    Ozaki, Norio
    Kuroda, Shigetoshi
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (04) : A31 - A32
  • [2] Cytochrome P450 2D6
    Owen, Ryan P.
    Sangkuhl, Katrin
    Klein, Teri E.
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (07): : 559 - 562
  • [3] Associations between cytochrome p450 2D6 genotype and antidepressant medication tolerance
    Mrazek, David A.
    Courson, Vicki L.
    Snyder, Karen A.
    O'Kane, Dennis J.
    Black, John L.
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 142S - 142S
  • [4] Cytochrome P450 2D6 genotype variation and venlafaxine dosage
    McAlpine, Donald E.
    O'Kane, Dennis J.
    Black, John L.
    Mrazek, David A.
    MAYO CLINIC PROCEEDINGS, 2007, 82 (09) : 1065 - 1068
  • [5] A DISCORDANCE BETWEEN P450 2D6 GENOTYPE AND PHENOTYPE
    Duricova, J.
    Perinova, I
    Kacirova, I
    Grundmann, M.
    Jeziskova, I
    Jurckova, N.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 75 - 75
  • [6] Allosteric effects of cytochrome P450 reductase on cytochrome P450 2D6
    Roberts, GCK
    Modi, S
    Gilham, DE
    Sutcliffe, MJ
    Lian, LY
    Primrose, WU
    Wolf, CR
    FASEB JOURNAL, 1997, 11 (09): : A789 - A789
  • [7] Cytochrome P450 2D6 as a Model Antigen
    Christen, Urs
    Holdener, Martin
    Hintermann, Edith
    DIGESTIVE DISEASES, 2010, 28 (01) : 80 - 85
  • [8] Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol
    Suzuki, Y
    Someya, T
    Shimoda, K
    Hirokane, G
    Morita, S
    Yokono, A
    Inoue, Y
    Takahashi, S
    THERAPEUTIC DRUG MONITORING, 2001, 23 (04) : 363 - 368
  • [9] Phenoconversion of Cytochrome P450 2D6: The Need for Identifying the Intermediate Metabolizer Genotype
    Berm, Elizabeth J. J.
    Risselada, Arne J.
    Mulder, Hans
    Hak, Eelko
    Wilffert, Bob
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (10) : 1025 - 1025
  • [10] Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate
    McConnachie, L
    Bodor, M
    Kowdley, K
    Levy, A
    Tung, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DA
    Ho, RJY
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (04) : 282 - 297